Michael Cohenuram, MD
Hematology & Oncology · Danbury, CTNPI 1043409691
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $628 of the $939 with a category attached, or 66.8%. 9 manufacturers reported payments, led by Merck at 47.5% of the total. Reporting peaked in 2019 at $572 and has fallen 97.3% since, to $15 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CT, where the typical reported total is $1,376.
Across 17 payments — averaging $55.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$446
- Jazz Pharmaceuticals Inc.$229
- Sanofi-aventis U.S. LLC$100
- Genentech, Inc.$77
- Bristol Myers Squibb$34
- E.r. Squibb & Sons, L.L.C.$15
- plus $39 from 3 others
Across 7 payments — averaging $2348.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10K
- F. Hoffmann-la Roche AG$6K
- Genentech, Inc.$668
What the payments were for
- Travel & lodging$17318%
- Food & beverage$62867%
- Education$13915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $446 |
| Jazz Pharmaceuticals Inc. | 2 | $229 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech, Inc. | 1 | $77 |
| Bristol Myers Squibb | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$939 in reported general payments places this provider in the 45th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 41 | $837,942 |
| TagrissoOsimertinib Mesylate | 49 | $826,811 |
| IbrancePalbociclib | 44 | $699,219 |
| KisqaliRibociclib Succinate | 13 | $185,479 |
| BrukinsaZanubrutinib | 12 | $180,559 |
| TabrectaCapmatinib Hydrochloride | 11 | $168,885 |
| EliquisApixaban | 44 | $61,941 |
| XareltoRivaroxaban | 25 | $31,539 |
| VeozahFezolinetant | 11 | $5,701 |
| Tamoxifen Citrate | 107 | $3,261 |
| Letrozole | 95 | $2,506 |
| Anastrozole | 106 | $1,934 |
| Prochlorperazine Maleate | 88 | $1,620 |
| Ondansetron OdtOndansetron | 48 | $1,067 |
| Hydroxyurea | 36 | $1,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $34 | $837,94241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Danbury
- Kevin JainDanbury$11K
- Eric MaDanbury$11K
- Robert KlossDanbury$9K
- Vincent RellaDanbury$9K
- Wenli GaoDanbury$8K
- Madhura HanmantgadDanbury$7K
- Katherine GarciaDanbury$5K
- Ravneet BajwaDanbury$5K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.